249 related articles for article (PubMed ID: 10400723)
1. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.
Hunter WD; Martuza RL; Feigenbaum F; Todo T; Mineta T; Yazaki T; Toda M; Newsome JT; Platenberg RC; Manz HJ; Rabkin SD
J Virol; 1999 Aug; 73(8):6319-26. PubMed ID: 10400723
[TBL] [Abstract][Full Text] [Related]
2. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.
Todo T; Feigenbaum F; Rabkin SD; Lakeman F; Newsome JT; Johnson PA; Mitchell E; Belliveau D; Ostrove JM; Martuza RL
Mol Ther; 2000 Dec; 2(6):588-95. PubMed ID: 11124059
[TBL] [Abstract][Full Text] [Related]
3. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.
Sundaresan P; Hunter WD; Martuza RL; Rabkin SD
J Virol; 2000 Apr; 74(8):3832-41. PubMed ID: 10729157
[TBL] [Abstract][Full Text] [Related]
4. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates.
Varghese S; Newsome JT; Rabkin SD; McGeagh K; Mahoney D; Nielsen P; Todo T; Martuza RL
Hum Gene Ther; 2001 May; 12(8):999-1010. PubMed ID: 11387063
[TBL] [Abstract][Full Text] [Related]
5. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.
Markert JM; Medlock MD; Rabkin SD; Gillespie GY; Todo T; Hunter WD; Palmer CA; Feigenbaum F; Tornatore C; Tufaro F; Martuza RL
Gene Ther; 2000 May; 7(10):867-74. PubMed ID: 10845725
[TBL] [Abstract][Full Text] [Related]
6. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
8. Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain.
Radbill AE; Reddy AT; Markert JM; Wyss JM; Pike MM; Akella NS; Bharara N; Gillespie GY
J Neurovirol; 2007 Apr; 13(2):118-29. PubMed ID: 17505980
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.
Markert JM; Razdan SN; Kuo HC; Cantor A; Knoll A; Karrasch M; Nabors LB; Markiewicz M; Agee BS; Coleman JM; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Weichselbaum RR; Fiveash JB; Gillespie GY
Mol Ther; 2014 May; 22(5):1048-55. PubMed ID: 24572293
[TBL] [Abstract][Full Text] [Related]
10. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
Markert JM; Liechty PG; Wang W; Gaston S; Braz E; Karrasch M; Nabors LB; Markiewicz M; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Gillespie GY
Mol Ther; 2009 Jan; 17(1):199-207. PubMed ID: 18957964
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.
Roth JC; Cassady KA; Cody JJ; Parker JN; Price KH; Coleman JM; Peggins JO; Noker PE; Powers NW; Grimes SD; Carroll SL; Gillespie GY; Whitley RJ; Markert JM
Hum Gene Ther Clin Dev; 2014 Mar; 25(1):16-27. PubMed ID: 24649838
[TBL] [Abstract][Full Text] [Related]
12. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1.
Yazaki T; Manz HJ; Rabkin SD; Martuza RL
Cancer Res; 1995 Nov; 55(21):4752-6. PubMed ID: 7585498
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207.
Oyama M; Ohigashi T; Hoshi M; Murai M; Uyemura K; Yazaki T
Jpn J Cancer Res; 2000 Dec; 91(12):1339-44. PubMed ID: 11123435
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice.
Bernstock JD; Vicario N; Li R; Nan L; Totsch SK; Schlappi C; Gessler F; Han X; Parenti R; Beierle EA; Whitley RJ; Aban I; Gillespie GY; Markert JM; Friedman GK
Cancer Gene Ther; 2020 Apr; 27(3-4):246-255. PubMed ID: 30918335
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
Nakano K; Todo T; Chijiiwa K; Tanaka M
Mol Ther; 2001 Apr; 3(4):431-7. PubMed ID: 11319903
[TBL] [Abstract][Full Text] [Related]
16. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.
Toda M; Rabkin SD; Martuza RL
Hum Gene Ther; 1998 Oct; 9(15):2177-85. PubMed ID: 9794202
[TBL] [Abstract][Full Text] [Related]
17. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.
Blank SV; Rubin SC; Coukos G; Amin KM; Albelda SM; Molnar-Kimber KL
Hum Gene Ther; 2002 Mar; 13(5):627-39. PubMed ID: 11916486
[TBL] [Abstract][Full Text] [Related]
18. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.
Brittle EE; Wang F; Lubinski JM; Bunte RM; Friedman HM
J Virol; 2008 Sep; 82(17):8431-41. PubMed ID: 18562543
[TBL] [Abstract][Full Text] [Related]
19. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
Zager JS; Delman KA; Malhotra S; Ebright MI; Bennett JJ; Kates T; Halterman M; Federoff H; Fong Y
Mol Med; 2001 Aug; 7(8):561-8. PubMed ID: 11591892
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel non-human primate model for preclinical gene vector safety studies. Determining the effects of intracerebral HSV-1 inoculation in the common marmoset: a comparative study.
Deisboeck TS; Wakimoto H; Nestler U; Louis DN; Sehgal PK; Simon M; Chiocca EA; Hochberg FH
Gene Ther; 2003 Aug; 10(15):1225-33. PubMed ID: 12858187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
